|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | LEADER surveillance program results for 2006:an activity and spectrum analysis of linezolid using clinical isolates from the United States(50 medical centers)显示文摘 | Jones RN Fritsche TR Sader HS | 2007 | Diagnostic Microbiology and Infectious Disease2007，59，： | 1 |
| 2 | Antimicrobial activity of DC-159a, a new fl uoroquinolone, against 1149 recently collected clinical isolates 显示文摘 | Jones RN Fritsche TR Sader HS | 2008 | Antimicrob Agents Chemother2008，52，： | 1 |
| 3 | Emerging metallo-beta-lactamase-mediated resistances: a summary report from the worldwide SENTRY antimicrobial surveillance program显示文摘 | Fritsche TR Sader HS Toleman MA | 2005 | Clin Infect Dis2005，414，： | 1 |
| 4 | Worldwide assessment of dalbavancinactivity and spectrum against over 6000 clinical isolates显示文摘 | Streit JM Fritsche TR Sader HS | 2004 | Clin Microbiol Infect2004，48，2： | 1 |
| 5 | Antimicrobial susceptibility of gram-positive bacteria isolated from European medical centres:results of the Daptomycin Surveillance Programme ( 2002 - 2004 ) 显示文摘 | Sader HS Streit JM Fritsche TR | 2006 | Clin Micmbiol Infect2006，12，： | 1 |
| 6 | Antimi- crobial activity of doripenem tested against prevalent Gram- positive pathogens: results from a global surveillance study (2003-2007)显示文摘 | FRITSCHE TR SADER HS STILLWELL MG et ol | 2009 | Diagn Microbiol Infect Dis2009，63，4： | 1 |
| 7 | Antimierobial spectrum and activity of NVP PDF-713, a novel peptide deformylase inhibitor, tested against 1837 recent gram-positive clinical isolates显示文摘 | Jones RN Fritsehe TR Sader HS | 2004 | Diag Microbiol Infect Dis2004，49，1： | 1 |
| 8 | Dalbavancinactivity against selected populations of antimicrobial-resistant gram-positive pathogens显示文摘 | Streit JM Sader HS Fritsche TR | 2005 | Diagn Microbiol Infect Dis2005，53，4： | 1 |
| 9 | Comparisons of parenteral broad-spectrum cephalosporins tested against bacterial isolates from pediatric patients: report from the SENTRY Anti- microbial Surveillance Program (1998-2004) 显示文摘 | Jones RN Sader HS Fritsche TR | 2007 | Diagn Microbiol Infect Dis2007，57，1： | 1 |
| 10 | Zyvox Annual Appraisal of Potency and Spectrum Program Results for 2006 : an activity and spectrum analysis of linezolid using clinical isolates from 16 countries显示文摘 | Jones RN Fritsche TR Sader HS | 2007 | Diagn Microbiol Infect Dis2007，59，2： | 1 |
| 11 | Antimicrobial susceptibility pattern comparisons among intensive care unit and general ward Gram- negative isolates from the Meropenem Yearly Susceptibility Test Informa- tion Collection Program(USA)显示文摘 | Rhomberg PR Fritsche TR Sader HS | 2006 | Diagn Microbiol Infect Dis2006，56，1： | 1 |
| 12 | Zyvox Annual Appraisal of Potency and Spectrum Program Results for 2006 : an activity and spectrum analysis of linezolid using clinical isolates from 16 coun- tries 显示文摘 | Jones RN Fritsche TR Sader HS | 2007 | Diagn Microbiol Infect Dis2007，59，： | 1 |
| 13 | Comparative activity and spectrum of broad - spectrum beta - lactams ( cefepime, ceftazidime, cefriaxone,piperacillin/tazobactam) tested against 12295 staphylococci and streptococci: report from the SENTRY antimicrobial surveillance program (North America: 2001 -2002 ) 显示文摘 | Fritsche TR Sader HS Jones RN | 2003 | Diagn Microbiol Infect Dis2003，47，： | 1 |
| 14 | Antimicrobial susceptibility pattern comparisons among intensive care unit and general ward Gram-negative isolates from the Meropenem Yearly Susceptibility Test Information Collection Program (USA)显示文摘 | Rhomberg PR Fritsche TR Sader HS | | 0，，： | 1 |
| 15 | LEADER surveillance program results for 2006 : an activity and spectrum analysis of linezolid using clinical isolates from the United States (50 medical centers) 显示文摘 | Jones TR Firtsche Sader HS | 2007 | Diagn Microbiol Infect Dis2007，59，： | 1 |
| 16 | Potency and spectrum trends for cefepime tested against 65746 clinical bacterial isolates collected in North American medical centers:results from the SENTRY Antimicrobial Surveillance Program (1998-2003)显示文摘 | Sader HS Fritsche TR Jones RN | 2005 | Diagn Microbiol Infect Dis2005，52，3： | 1 |
| 17 | Quality control guidelines for BAL9141 (Ro 63-9141),an investigational cephalosporin,when reference MIC and standardized disk diffusion susceptibility test methods are used显示文摘 | ANDEREGG TR JONES RN SADER HS | 2004 | J Clin Microbiol2004，42，7： | 1 |
| 18 | Comparative activity and spectrum of broad-spectrum beta-lactams(cefepime,ceftazidime,cefriaxone,piperacillin/tazobactam) tested against 12295 staphylococci and streptococci:report from the SENTRY antimicrobial surveillance program (North America:2001-2002)显示文摘 | Fritsche TR Sader HS Jones RN | 2003 | Diagn Microbiol Infect Dis2003，47，： | 1 |
| 19 | Antimicrobial activities of ceftaroline and ME1036 tested against clinical strains of community-acquired methicillin-resistant staphylococcus aureus显示文摘 | Sader HS Fritsche TR Jones RN | 2008 | Antimicrob Agents Chemother2008，52，10： | 1 |
| 20 | Accuracy of three automated systems ( MieroSean WalkAway, VITEK, and VITEK 2) for sus- ceptibility testing of Pseudomonas aeruginosa against five broad- spectrum beta-laetam agents 显示文摘 | Sader HS Fritsche TR Jones RN | 2006 | J Clin Mierobiol2006，44，3： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员